Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Net Margin: 2009-2025

Historic Net Margin for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to 14.15%.

  • Aytu Biopharma's Net Margin rose 1185.00% to 14.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.46%, marking a year-over-year increase of 705.00%. This contributed to the annual value of 0.93% for FY2025, which is 603.00% up from last year.
  • Per Aytu Biopharma's latest filing, its Net Margin stood at 14.15% for Q3 2025, which was up 3,353.93% from 0.41% recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Net Margin peaked at 14.15% during Q3 2025, and registered a low of -220.22% during Q1 2022.
  • Its 3-year average for Net Margin is -3.91%, with a median of -3.63% in 2023.
  • As far as peak fluctuations go, Aytu Biopharma's Net Margin tumbled by 12,345bps in 2021, and later spiked by 18,855bps in 2023.
  • Aytu Biopharma's Net Margin (Quarterly) stood at -49.94% in 2021, then surged by 2,447bps to -25.47% in 2022, then spiked by 2,099bps to -4.48% in 2023, then surged by 523bps to 0.76% in 2024, then surged by 1,185bps to 14.15% in 2025.
  • Its Net Margin was 14.15% in Q3 2025, compared to 0.41% in Q2 2025 and 0.29% in Q1 2025.